Angiotensin Ii Acetate
FDA-approved product (solution, intravenous), marketed as Angiotensin Ll Acetate, Giapreza.
- Registered studies
- 10
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Hypotension
- Septic shock
- Shock
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other cardiac stimulants
- FDA pharmacologic class
- Vasoconstrictor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis66.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
10registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Angiotensin Ii Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
NCT06482853 · start 2025-01-23
Registered record
- Registry ID
- NCT06482853
- Conditions
- Obesity; Hypertension
- Interventions
- Angiotensin-(1-7); Saline
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Recruiting
- Start
- 2025-01-23
- Completion
- 2029-03
- Enrolment
- 52
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionObesity; HypertensionInterventionAngiotensin-(1-7); SalinePhaseEarly phase 1Registry statusRecruitingSafety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury
NCT06282965 · start 2024-05-28
Registered record
- Registry ID
- NCT06282965
- Conditions
- Traumatic Brain Injury
- Interventions
- Angiotensin (1-7); Sterile saline
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2024-05-28
- Completion
- 2027-09
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTraumatic Brain InjuryInterventionAngiotensin (1-7); Sterile salinePhasePhase 1 / Phase 2Registry statusRecruitingA Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
NCT05709444 · start 2022-12-26
Registered record
- Registry ID
- NCT05709444
- Conditions
- Kidney Disease
- Interventions
- Bremelanotide; RAAS inhibition therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2022-12-26
- Completion
- 2024-04-26
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney DiseaseInterventionBremelanotide; RAAS inhibition therapyPhasePhase 2Registry statusCompletedAngiotensin-(1-7) Cardiovascular Effects in Aging
NCT05301192 · start 2022-12-09
Registered record
- Registry ID
- NCT05301192
- Conditions
- Aging
- Interventions
- Angiotensin-(1-7); Saline
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Recruiting
- Start
- 2022-12-09
- Completion
- 2026-12
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAgingInterventionAngiotensin-(1-7); SalinePhaseEarly phase 1Registry statusRecruitingAngiotensin-(1-7) and Energy Expenditure in Human Obesity
NCT03777215 · start 2019-09-26
Registered record
- Registry ID
- NCT03777215
- Conditions
- Obesity
- Interventions
- Angiotensin-(1-7); Saline
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Active not recruiting
- Start
- 2019-09-26
- Completion
- 2026-12
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionObesityInterventionAngiotensin-(1-7); SalinePhaseEarly phase 1Registry statusActive not recruitingAngiotensin 1-7 in Obesity Hypertension
NCT03604289 · start 2019-04-01
Registered record
- Registry ID
- NCT03604289
- Conditions
- Obesity; Hypertension
- Interventions
- Angiotensin-(1-7); Saline
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2019-04-01
- Completion
- 2023-06-03
- Enrolment
- 8
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionObesity; HypertensionInterventionAngiotensin-(1-7); SalinePhaseEarly phase 1Registry statusTerminatedAngiotensin-(1-7) in Peripheral Arterial Disease
NCT03240068 · start 2017-09-01
Registered record
- Registry ID
- NCT03240068
- Conditions
- Peripheral Arterial Disease
- Interventions
- Angiotensin 1-7; Saline
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2017-09-01
- Completion
- 2020-03-09
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPeripheral Arterial DiseaseInterventionAngiotensin 1-7; SalinePhaseEarly phase 1Registry statusTerminatedBlood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure
NCT02591173 · start 2016-02
Registered record
- Registry ID
- NCT02591173
- Conditions
- Autonomic Nervous System Disorders; Pure Autonomic Failure; Shy-Drager Syndrome; Orthostatic Hypotension, Dysautonomic
- Interventions
- Angiotensin-(1-7); Saline
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2016-02
- Completion
- 2020-07
- Enrolment
- 7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAutonomic Nervous System Disorders; Pure Autonomic Failure; Shy-Drager Syndrome; Orthostatic Hypotension, DysautonomicInterventionAngiotensin-(1-7); SalinePhaseEarly phase 1Registry statusTerminatedMetabolic Effects of Angiotensin-(1-7)
NCT02646475 · start 2016-02
Registered record
- Registry ID
- NCT02646475
- Conditions
- Obesity; Insulin Resistance; Hypertension; Metabolic Cardiovascular Syndrome
- Interventions
- Angiotensin-(1-7); Saline
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Recruiting
- Start
- 2016-02
- Completion
- 2029-12
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionObesity; Insulin Resistance; Hypertension; Metabolic Cardiovascular SyndromeInterventionAngiotensin-(1-7); SalinePhasePhase 1Registry statusRecruitingIntravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study
NCT01393782 · start 2011-07
Registered record
- Registry ID
- NCT01393782
- Conditions
- Septic Shock
- Interventions
- Angiotensin II
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-07
- Completion
- 2014-01
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeptic ShockInterventionAngiotensin IIPhasePhase 1Registry statusCompleted